The COHCCC Director has a wide array of advisory inputs to assist in planning for the Center's future andevaluating the outcomes of Center program and policy implementation. The most important of these is theday-to-day decision-making body, the Cancer Center Leadership Committee. This group consists of thetraditional senior leaders of the Center (Deputy and Associate Directors), as well as the Program Co-Leadersand several other key senior members of the Center. All plans either originate in or pass through this group.In recent years, our External Advisory Committee has played an ever larger role in reviewing our plansand advising on our course of action; the EAC is also particularly important in its evaluative function. In thisprogram cycle, the Director has established two new committees of CC leaders to advise on the overhaulingof the Center's clinical trials apparatus and in developing new disease-based research programs. Theseare, respectively, the Clinical Research Governance Board and the Cancer Center Task Force forDisease Program Development. To assist in Institutional strategic planning, all senior scientific, clinical,and administrative leaders form the Clinical and Scientific Executive Team. City of Hope CorporateBoards of Directors (for the Parent Corporation, as well as for the Beckman Research Institute [BRI] andNational Medical Center [NMC]) provide a lay perspective to the Director on many issues and, ultimately,approve the Cancer Center's strategic directions. Finally, for consultation relating to academic issues orclinical programs, respectively, the Director meets regularly with the BRI Council of Chairs and the NMCCouncil of Chairs. The Cancer Center Minority Task Force advises on interlocking initiaves forcommunity engagement in CCARE. In the upcoming program period, there are several major initiatives forwhich our planning processes and advisory bodies are fully engaged. These include: (1) full implementationof the three developing cores; (2) full implementation of the CCARE initiative; (3) the evolution of one orseveral clinical programs into Cancer Center disease-based research programs; and (4) full implementationof our long-range plan for the development of cancer prevention and population science research.
| Aslamy, Arianne; Oh, Eunjin; Olson, Erika M et al. (2018) Doc2b Protects ?-Cells Against Inflammatory Damage and Enhances Function. Diabetes 67:1332-1344 |
| Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707 |
| Weitzel, Jeffrey N; Chao, Elizabeth C; Nehoray, Bita et al. (2018) Somatic TP53 variants frequently confound germ-line testing results. Genet Med 20:809-816 |
| Ghose, Jayeeta; Viola, Domenico; Terrazas, Cesar et al. (2018) Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 7:e1486948 |
| Castanotto, Daniela; Zhang, Xiaowei; Alluin, Jessica et al. (2018) A stress-induced response complex (SIRC) shuttles miRNAs, siRNAs, and oligonucleotides to the nucleus. Proc Natl Acad Sci U S A 115:E5756-E5765 |
| Awasthi, Sanjay; Tompkins, Joshua; Singhal, Jyotsana et al. (2018) Rlip depletion prevents spontaneous neoplasia in TP53 null mice. Proc Natl Acad Sci U S A 115:3918-3923 |
| Röth, Daniel; Chiang, Abby J; Hu, Weidong et al. (2018) Two-carbon folate cycle of commensal Lactobacillus reuteri 6475 gives rise to immunomodulatory ethionine, a source for histone ethylation. FASEB J :fj201801848R |
| Li, Yi-Jia; Du, Li; Aldana-Masangkay, Grace et al. (2018) Regulation of miR-34b/c-targeted gene expression program by SUMOylation. Nucleic Acids Res 46:7108-7123 |
| Maestrini, Davide; Abler, Daniel; Adhikarla, Vikram et al. (2018) Aging in a Relativistic Biological Space-Time. Front Cell Dev Biol 6:55 |
| Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60 |
Showing the most recent 10 out of 1396 publications
